Ionis Confident In Wainua Expansion Strategy Despite Alnylam Trial Changes

Amvuttra and Wainua Are Rivals In The Space

Investors are closely following a Phase III study testing Wainua in ATTR cardiomyopathy, which could read out early in 2025.

runners
Ionis and Alnylam are competing in cardiomyopathy • Source: Shutterstock

Ionis Pharmaceuticals, Inc. CEO Brett Monia said the company remains confident in the Phase III trial design for Wainua (eplontersen) for the treatment of hereditary transthyretin mediated amyloidosis (ATTR) cardiomyopathy, days after rival Alnylam Pharmaceuticals Inc. made changes to the endpoint and timeline of an ongoing Phase III trial testing Amvuttra (vutrisiran) for the same indication.

Key Takeaways
  • Ionis responded to investor questions about the Phase III development program for Wainua in ATTR cardiomyopathy, after Alnylam announced changes to the study of a rival drug....

Alnylam’s announcement on 15 February during the company’s fourth quarter sales and earnings call startled some investors, as the Phase III study, HELIOS-B, had been on track to read out...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.